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ABSTRACT  
 
The global prevalence of type 2 diabetes mellitus (T2DM) in adolescents and young adults is 
dramatically increasing.  As with older onset type 2 diabetes, the major predisposing  risk factors  are 
obesity, family history and sedentary lifestyle. Onset of diabetes at a younger age is associated with 
longer disease exposure and increased risk  for  chronic complications affecting more individuals of 
working age and accentuating adverse societal impact of the disease. Evidence is also accumulating  
that young diabetic cohorts represent an aggressive phenotype  leading to  premature development 
of complications with an adverse impact on quality of life and unfavourably influencing long term 
outcomes, raising the possibility of a future   public health catastrophe.   In this review we describe 
the epidemiology and  current knowledge regarding  pathophysiology, risk factors, complications 
and management of type 2 diabetes in adolescents and young adults. 
 
 
KEY WORDS 
Type 2 diabetes, early-onset, young, youth, children, adolescents. 
 
Word count: 5580 words (Not  Including sub headings) 
 
 
  
 3 
 
INTRODUCTION 
The global prevalence of adults with diabetes is around 8% (>90% of whom have T2DM)with  
projections to increase to over 10% by 20401. While the impact of  increasing prevalence of diabetes 
among older adults is becoming ever more apparent, the rising number of young people with 
T2DM(T2DMY) is a more recent and particular concern.  Earlier onset  leads to longer lifetime 
exposure to hyperglycaemia and consequently greater propensity for long term complications. In 
addition, T2DMY may have a more rapid and disruptive natural history than T2DM presenting later 
in life, leading to early morbidity and poor quality of life2. Moreover,T2DMY affects more individuals 
of working age which further accentuates its adverse societal impact.  
 
For  this review we have defined T2DMY as onset of type 2 diabetes ( ADA and WHO criteria3,4)  in 
adolescents and young adults up  to age 40 years excluding secondary diabetes (drug- or chemical-
induced, exocrine pancreas disease, genetic defects), MODY, gestational diabetes and rare forms of 
diabetes. We examine  evidence in support of the hypothesis that T2DMY is a distinct pathological 
entity characterised by a more aggressive phenotype than T2DM presenting in later  life.  
SEARCH STRATEGY AND SELECTION CRITERIA 
References  were identified through searches of Medline, PubMed and Web of Science for articles 
published  January 2000 to April 2017. Search terms included "early-onset", "young adults", "youth", 
“children”, and "adolescents" in combination with the term "diabetes" and “type 2 diabetes”. 
Studies had to be in human populations, published in English  and with a defined age-range for 
diagnosis of T2DMY.  Articles were excluded if they were case reports, editorials, small studies or 
studies that the authors felt had methodological limitations, studies on type 1 diabetes, gestational 
diabetes or MODY. Although T2DM across adolescents and younger adults can be seen as a 
continuum, inevitably there are some distinct features within age groups that are influenced by life 
events at different ages. To provide further clarity of such distinctions, we have identified  studies 
that have included only a specific age range. 
 
 
EPIDEMIOLOGY 
 
 T2DM is  increasingly diagnosed in children, adolescents and younger adults. Prevalence estimates 
suggest a 30·5% increase in T2DM amongst US youth aged 10 to 19 years between 2001 and 2009, 
accounting for prevalence of 0·48 per 1000 in this age group5. Recent data from the SEARCH study 
showed an annual increase of 7.1% in the incidence of T2DM (9 cases per 100,000 in 2002 -2003 to 
12.5 cases per 100,000 in 2011-2012) amongst 10-19 year olds in the USA with significant relative 
increases in all ethnic groups compared to non Hispanic Whites6. A nationwide screening 
programme of diabetes among children aged 6 to 18 years,  in Taiwan between 1992 and 1999, 
found an incidence of newly diagnosed T2DM of 6·5 per 100,000 compared with 1.5 per 100,000 for 
T1DM7.The International Diabetes Federation estimated that in the year 2000 young adults aged 20-
39 years with T2DM numbered approximately 23 million worldwide (13% of 177 million adults with 
diabetes8). By 2013 this had increased to an estimated 63 million (16% of 382 million adults with 
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T2DM9-11), the biggest increases being  in Africa, South East Asia and the Western Pacific regions 
(Figure 1).  
 
Figure 1. Young adults (20-39 years) with T2DM worldwide (millions)9 
 
 
* refers to % of Total number of people diagnosed with type 2 diabetes 
 
A study of the age specific incidence of T2DM in the UK reported a significant increase in the 
proportion of people aged ≤40 years at diagnosis (Figure 2)12 over a 20 year period. The standardized 
incidence ratio (per 100,000 population) of newly diagnosed T2DM aged <40 years increased from 
217 in 1996-2000 to 598 in 2006-2010.  
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Figure 2. Age specific incidence of newly diagnosed T2DM per 100,000 amongst males and females 
aged less than 40 years at diagnosis (modified with permission)12  
 
 
 
 
 
 
 
Increasing numbers of children, adolescents and young adults with T2DM have been reported across 
most regions of the world.  In the UK, a higher prevalence is reported  in people of South Asian, 
African and African-Caribbean origin compared with white European populations13. Individuals born 
in the USA in the year 2000 have a risk for diabetes by age 40 years of approximately 2·5% for men 
and 5% for women., These estimates  are doubled for Hispanic and black persons suggesting that 
certain ethnic groups are disproportionately affected 14.  However, apparent ethnic differences 
based on  regional variations in prevalence (table 1), have the limitation that the diagnostic criteria 
and methods of data collection are not always consistent 15-17.  
 
PATHOPHYSIOLOGY 
 
Decline in beta cell function 
 
The  mechanisms leading to  development of T2DMY are similar to those  in T2DM amongst older 
adults. However, the speed of onset, severity and interplay  of decreased insulin sensitivity and 
defective insulin secretion  during the development of T2DMY may differ from older presentations of 
T2DM18. In adolescents with T2DM, as in later onset T2DM, the initial deterioration in beta-cell 
113
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function is characterised by loss of first phase nutrient-stimulated insulin secretion6.  However, the 
second phase of nutrient-induced insulin secretion may be compromised earlier in the pathogenic 
process in younger individuals with T2DM18,19-.    A case-control study of  African-American and white 
Europids found that obese adolescents with T2DM for about 1.5 years have about a 75% decrease of 
first phase  and a 50% decrease of second phase insulin secretion compared with obese non diabetic 
peers20. Such a decrease in second phase insulin secretion would take  more than a decade to 
emerge in most T2DM patients presenting in middle or later life21-22. Emerging evidence suggests 
that loss of beta cell function is accelerated in T2DMY. A 20-35 % decline in beta cell function 
annually in 10-19 year olds has been reported  compared to the ~7% loss in older individuals with 
T2DM23. These findings are consistent with  data from a small but detailed clamp study in this age 
group24. Separate observational studies in adolescents of different ethnic groups have similarly 
confirmed the early deterioration of beta-cell function with T2DMY:  this was closely  associated with 
the severity of insulin resistance (IR) in African-American adolescents but less so in white Europids 
and South Asians 25,26.      Thus,   accelerated decline of beta cell function appears to make an  
important contribution to the development of T2DM in early life.  The reasons for this rapid failure 
of both phases of nutrient-stimulated insulin secretion are unclear but suggest that T2DMY may 
have more aggressive course with faster loss of beta cell function than T2DM presenting later in life.  
 
Obesity induced mechanisms 
 
The prevalence of obesity among children, adolescents and young adults with  T2DM is much greater 
than in older adults (eg. >80% versus 56% in a recent study26) and analyses of large databases have 
confirmed  a strong inverse association between BMI and age at diagnosis of T2DM27.  When T2DM 
presents in later life the severity of IR is often greater amongst those with a history of protracted 
and severe obesity, particularly with excess visceral adiposity28.  In contrast, a relationship between 
the degree of obesity and the extent of IR has not been a consistent finding in studies of adolescents 
with T2DM, and there are insufficient data to determine the involvement of visceral adiposity in this 
age group 19. However, IR is directly related to an increased percentage of fat in muscle and liver in 
all age groups6 , and younger people with T2DM can have much higher (up to 3 times) amounts of 
liver fat compared with BMI-matched non-diabetic controls and compared with presentations  of 
T2DM in middle and later life24, 
 
Compared with non-obese adolescents, obese adolescents are reported to have chronically 
increased circulating free fatty acids (FFA) which decrease insulin sensitivity   and may contribute to  
increased  reactive oxygen species and impair insulin secretion29.   Chronic low-grade inflammation 
contributes to development of insulin resistance in T2DM, typically involving excess production of   
adipokines  (tumour necrosis factor-α (TNFα), interleukin -1beta and high sensitivity C-reactive 
protein)29,30. Increased circulating concentrations of these pro-inflammatory markers are reported in 
adolescents with T2DM30 .While obesity is clearly a prominent risk factor for T2DMY, studies 
focussed on IR, lipid metabolism and inflammation corroborate evidence in the previous section 
suggesting that the development of ‘diabetic’ hyperglycaemia in this age group appears to be more 
strongly dependent on beta-cell failure than T2DM in later life.  
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KEY DRIVERS FOR T2DMY 
 
Early life determinants 
 
Changes in the intrauterine environment influence development of obesity and type 2 diabetes in 
adolescents and young adults more strongly than in later life. Maternal undernutrition and 
overnutrition are associated with a greater increased risk of obesity and type 2 diabetes in 
adolescence and early adulthood than in later life,31,32. This may depend in part on the extent and 
timing of ‘catch-up’ growth in underweight offspring and the extent of excess adiposity in those with 
overnutrition sustained beyond the first year of  life33.  Thus, in a large prospective study, rapid 
weight gain during the first 4 months of life was associated with an increased risk of overweight at 
age 7 years34, while post-partum under nutrition increased the risk of obesity and type 2 diabetes in 
young adults35.  Also, T2DM before age 20 years emerges 1-2 years earlier in offspring exposed to 
hyperglycaemia in utero31.  These observations have been attributed in part to  epigenetic influences 
of the intra-uterine and early post-natal environment on metabolic programming, but the molecular 
mechanisms remain speculative36.   
 
 
Diet and obesity 
 
The global pandemic of overweight and obesity  now affects 36.9% of men,38% of  women,  23.8%  
of boys and 22.6% of girls37.  Although the  causes of obesity in children and adolescents are 
complex, obesity is clearly a driver for the upsurge in T2DMY  and changes in lifestyle  account for 
much of the increased prevalence of obesity and T2DM in pre- and early- adult life 38. Increasing 
consumption of calorie dense foods, and  sugar-rich drinks and  decreased  physical activity are  the 
main contributors amongst youth39. Regular consumption of sweetened beverages increases energy 
consumption by about 10%, while increased portion sizes, access to fast foods and targeted 
advertising of snacks  increase adiposity in children, adolescents and young adults40,41.  The 
widespread use of corn derived fructose syrup as a sweetening agent in ‘fizzy’ drinks has a 
substantial impact on  development of adiposity, IR, hyperglycaemia and other cardio-metabolic risk 
factors in the young 42,43 .   Indeed, the SEARCH study showed few differences in macronutrient or 
fibre intake between youths with T1DM versus T2DM, but those with T2DM consumed twice the 
amount of sweetened beverages 44.    
 
 
Physical activity 
Physical inactivity is  associated with increased risk of obesity. However, owing to methodological 
deficiencies and lack of reliable baseline data,  it is difficult to quantify the secular changes in leisure 
time activity in adolescents and younger adults45 .Nevertheless,  better transportation, television 
viewing and video games all contribute to sedentary behaviours  45. Physical activity declines further 
in adolescents compared with younger children and only a small proportion   meet   recommended 
levels, eg recent surveys in Europe and North America indicate that about 80% of 13-15 year-olds 
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undertake moderate or vigorous exercise for less than 60 minutes per day, with girls being less 
active than boys 46-49  . Physical inactivity amongst youth  is associated with increased risk of  
metabolic  syndrome , insulin resistance and type 2 diabetes. 50-51. 
 In the Bogulusa Heart Study of  young adults aged 20-38 years, an inverse relationship was observed 
between leisure time physical activity and risk factors for insulin resistance50. Similarly,  in the 
CARDIA study of 18 to 30 year olds, there was  a strong association between physical inactivity and  
risk of type 2 diabetes , hypertension and metabolic syndrome 51 . Although aerobic exercise can 
delay or prevent the development of type 2 diabetes in older adults, the expected metabolic 
benefits derived from aerobic activity are comparatively less in those with T2DMY52  . Thus, while 
lack of physical activity makes an important contribution to the pathogenesis of T2DMY the potential 
for increased  physical activity as a treatment strategy needs further elucidation. 
 
Socio-economic factors 
 
Socio-economic deprivation within affluent  societies is a risk factor for obesity and type 2 diabetes 
especially amongst inner city populations. For young individuals at least, this  is attributable more to 
lifestyle choices for energy dense ‘convenience’ foods and sedentary habits than an absolute lack of 
availability or affordability of healthier options, often reflecting educational factors and local 
practices 54,56 . The impact of deprivation is  magnified by the predisposition to T2DM across certain 
ethnic migrant communities57.  However, it is difficult to dissect the contributions of genetic 
determinants, environmental influences and cultural constraints, especially for pre-adult and early 
adult development of T2DM  54-56  
 
Socio-economic interventions can relieve absolute deprivation but do not necessarily alter individual 
lifestyle choices. Thus,  re-housing or changing facilities within neighbourhoods can bring about 
modest reductions in the incidence of obesity and T2DM, but the complex interactions of multiple 
diabetogenic factors continue to mask  appreciation of the contribution of individual determinants 
of risk58-59.   Indeed, obesity is also common amongst members of affluent societies who are not 
deprived, and this cannot be accounted for by ethnicity or culture, thereby implicating individual 
lifestyle and behavioural choices as risk factors having a greater influence on the pathogenesis of 
T2DMY60-61. 
 
 
Other risk factors 
 
Family history 
 There is an  inverse association between the strength of a family history of T2DM and  age of onset 
of T2DM62. In a   study of 5193 subjects from different ethnic backgrounds, including Anglo-Celtic, 
Indian, Australian Aboriginal and Pacific Islander, age of onset of diabetes reduced by 1·7 years for 
every 10% increase in family members affected by diabetes62. Similar associations occur  in Korean9, 
Chinese63 and Indian populations64. In white Europeans, T2DM patients diagnosed at  <55 years had  
a stronger and different genetic predisposition than subjects diagnosed later 65. In a large Scottish 
population-based cohort study , genetic risk of T2DM conferred by 61 gene variants was associated 
with a younger age at diagnosis and younger age at insulin treatment66.  Although parental diabetes 
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strongly influences early-onset T2DM, it is difficult to disentangle genetic  and socially-acquired 
factors. For example, increased risk of T2DMY amongst Afro-Caribbean and South Asian 
communities is strongly influenced by cultural factors, especially amongst women, but attempts to 
analyse this through studies of migrant individuals have noted the tendency of migrants to adopt a 
mix of cultures that still precludes dissection of specific risk factors67-69.   
 
Studies in Mexican and Asian populations have identified several mutations associated with 
T2DMY70-73. The high prevalence of parental T2DM in subjects diagnosed with T2DMY could reflect a 
stronger genetic predisposition, even when monogenic diabetes is excluded. This suggests that 
efforts to define T2DM genes by linkage may be more powerful if focused on young adults with 
diabetes, raising the question whether T2DM in older populations has a relatively smaller genetic  
and a stronger environmental influence65. 
 
 
Gender and Polycystic ovarian syndrome (PCOS) 
 
 T2DMY is more common amongst females across all ethnicities. Incidence rate amongst females 
was nearly twice that of males in the SEARCH study6. Female gender is associated with early-onset 
diabetes (<30 years) in Bangladesh74 and Jamaica75,  attributed to the increase in overweight and 
obesity. Gestational diabetes is a  risk factor for T2DM and can  trigger  onset of T2DM in youth76. 
The risk of T2DM is significantly elevated in young women diagnosed with PCOS, and is possibly 
related to insulin resistance77,78.  The Australian Longitudinal Study on Women's Health found that in 
women aged 28-33 years and of similar BMI, the prevalence of T2DM was 5·1% in women with  and 
0·3% in women without PCOS 76. Studies in the USA and Asia of women aged 20-35 years, report a 
three-fold increased rate of T2DM in those with PCOS  compared with the general population77.  
Non-alcoholic fatty liver disease (NAFLD) 
 Non-Alcoholic Fatty Liver Disease (NAFLD) appears to be a stronger risk factor for T2DMY than 
presentations of T2DM in middle and later life .NAFLD is often doubled in adolescents and young 
adults with T2DM, alongside insulin resistance and hyperinsulinaemia79-80. An  Indian study noted a 
54.7% prevalence of NAFLD in patients with T2DM aged 25-40 years, with liver enzymes being higher  
than patients aged >40 years81.  In a cross-sectional study across 12 centres in the USA, biopsy-
confirmed NAFLD was 43% higher in children (<18 years of age) with T2DM and 34% higher in 
children with pre-diabetes than non-hyperglycaemic peers82.   The extent to which excess ectopic fat 
and particularly NAFLD are driving insulin resistance in T2DMY remains unclear, but alcohol does not 
appear to be a significant cause of fatty liver in this age group.  
 
CLINICAL CHARACTERISTICS  
 
The clinical characteristics of T2DMY show substantial overlap with type 1 diabetes mellitus (T1DM) 
and T2DM from which it needs to be differentiated. The early loss of insulin secretory capacity in 
pre-adult and early adult presentations of T2DM is similar to the demise of beta-cell function in 
T1DM, while the high degree of obesity seen in T2DMY is an exaggeration of that seen with later 
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adult-onset T2DM. Adolescents who develop T2DM also typically show similar clinical features of 
insulin resistance, dyslipidaemia, hypertension and PCOS to later presentations of T2DM, but the 
long-term consequences of early-onset complications are only now becoming apparent83-84.    
Despite the shared clinical characteristics, T2DMY can be differentiated from T1DM and T2DM based 
on certain phenotypic characteristics (Table 1). Compared to T1DM,individuals with T2DMY do not 
have evidence of autoimmunity  and typical symptoms of diabetes may be absent in a third of all 
patients 85.  They have a higher prevalence of hypertension and a greater adverse cardiovascular risk 
profile than  with T1DM and are more likely to be on  statins and anti-hypertensives86,87,89. There is 
also a higher prevalence of microvascular complications at a shorter disease duration compared to 
T1DM88.  
Compared to late onset T2DM, a significant proportion  (around 65%) of individuals with T2DMY are 
diagnosed based on self reported symptoms than through regular health checks85 and have a higher 
prevalence of a diabetes family history, diastolic hypertension and worse glycaemic control26,27. 
Furthermore, T2DMY is associated with a shorter time to start insulin than T2DM in older adults89,90.  
 
Table 1:  Differences between T1DM, T2DMY and T2DM 
 
 T1DM T2DMY T2DM 
Gender  No difference Female preponderance  Slight male preponderance 
Ethnicity Common in white Caucasians 
although all ethnic groups 
affected 
All ethnic  groups but Hispanics, 
African -Americans, native 
Americans and South Asians 
disproportionately more affected 
All ethnic  groups but Hispanics, 
African -Americans, native 
Americans and South Asians 
more affected 
Clinical features  Often underweight, sometimes 
mildly obese 
Features of insulin resistance less 
likely 
Usually overweight, obese or 
severely obese 
Metabolic Syndrome 
Insulin resistance, dyslipidaemia, 
hypertension, PCOS 
Usually overweight, obese or 
severely obese 
Metabolic Syndrome 
Insulin resistance, dyslipidaemia, 
hypertension, PCOS 
Autoimmunity Present Absent Absent or rare 
Presentation Often acute onset/ketoacidosis Slow/asymptomatic /rarely 
ketoacidosis 
Slow/asymptomatic 
Family history Commonly no family association Very strong Strong 
Diabetes Management Insulin Rapid progression to insulin 
>50%  between 2-5 years since 
diagnosis 
Gradual progression to Insulin 
Usually >5 years since diagnosis 
 
Individuals with T2DMY develop adverse metabolic and cardiovascular risk profiles more rapidly and 
much sooner after diagnosis than T2DM in middle and later life91.  Whilst the features associated 
with these adverse risk profiles  are not dissimilar a greater  intensity and greater potential impact 
on complications is likely87. For example, a higher prevalence of obesity and metabolic syndrome (up 
to 70%) has been reported in   individuals with T2DMY and  sub-diabetic hyperglycaemia (IFG and 
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IGT),91,92.    Early-onset of T2DM in adults has also been associated with a higher HbA1c  in US9, 
Asian10and UK93populations. In a large proportion of young adult Sri Lankan patients with T2DM, 
aged 14-45 years (median age 38yrs), there were increased  apolipoprotein B (54% >1.2 g/L) and 
triglycerides (33% >1.5 mmol/L),  consistent with increased CV risk94. Similar results were reported  
in a  UK population95. Moreover, apolipoprotein B levels remained significantly higher among early-
onset T2DM subjects compared to older adults with T2DM despite statin treatment supporting the 
elevated atherogenic risk in the former 94,96. 
COMPLICATIONS 
Earlier onset of type 2 diabetes is associated with a greater lifetime risk of diabetes-related 
complications97. Several cross-sectional studies have suggested that the burden of diabetes 
complications is greater for T2DMY than T1DM and later onset T2DM. Overall life expectancy 
amongst those diagnosed with T2DM at 20-40 years is reduced by 14 years in men and 16 years in 
women,98 compared to the non-diabetic population.  
 
Microvascular complications 
 
Studies have reported a significantly higher prevalence of microvascular complications in T2DMY 
compared to T1DM and later onset T2DM102,103,106. The burden of microvascular complications and 
co-morbidites (diabetic kidney disease, retinopathy and peripheral neuropathy) was significantly 
greater amongst adolescents and youth with T2DM compared to those with T1DM in the SEARCH 
study106. In studies comparing patients with T1DM and T2DMY, rates of microalbuminuria were 
significantly greater in the latter and associated with a faster progression to macroalbuminuria107. 
T2DMY also had a  four times greater risk of renal failure and relatively poor survival outcomes when 
compared with T1DM of a similar age and diabetes duration9,27,92,102. In a longitudinal observational 
multi-ethnic cohort study of young people in the USA with T2DM diagnosed at <20 years of age, the 
prevalence of diabetic peripheral neuropathy was comparable to that reported in older adults with 
T2DM and three times higher when compared to young people with T1DM107. In a UK study, the 
prevalence of retinopathy at all stages amongst T2DMY patients (age of onset <40years) was 
comparable with T1DM patients despite  a shorter duration of diabetes and similarly poor glycaemic  
control, but there was  a higher prevalence when corrected for diabetes duration104.   An increased   
frequency of retinopathy, advanced eye disease and photocoagulation was noted in a large 
retrospective study of early onset versus late onset T2DM subjects in Asia 105. Another study found 
that 10 years after diagnosis  prevalence of retinopathy amongst T2DMY patients was significantly 
higher than those  with later onset T2DM, and identified hypertension and suboptimal glycaemic 
control as predominant contributing risk factors103. 
 
 
 
Macrovascular Complications 
 
Compared to non-diabetic individuals of similar age, T2DMY subjects have a substantially greater risk 
of macrovascular disease89.   In a large prospective study  comparing earlier versus later onset of 
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T2DM in adults (mean age at diagnosis 37.6 years v 60 years), the risk of developing any 
macrovascular complication  was twice as high in those with  earlier onset108. Further, T2DMY 
patients had a 14-fold higher risk of developing an MI than non-diabetic control subjects, whereas 
the risk of an MI would be much less (typically 2-4 fold higher) in T2DM presenting in middle and 
later life 108.  In Hong Kong, where 20% of recently diagnosed T2DM occurs in those aged < 40 years , 
a 7 year prospective study reported that when adjusted for age patients with T2DMY had 30-50% 
excess risk of CV  and renal disease compared with late-onset disease109.   At diagnosis the T2DMY 
patients had a similar or worse metabolic risk profiles compared with late-onset disease, and the 
risks for CV  and renal complications at any given age were greater in  T2DMY, predominantly driven 
by longer disease duration109. During the sixth decade, T2DMY was associated with approximately 
double the risk of CVD, CKD and all-cause mortality109.  
Significant differences in surrogate markers of CV disease between T1DM, later onset T2DM and 
T2DMY are  reported  110-112. Compared with T1DM and young control subjects, T2DMY patients 
(aged 14-30 years) show a greater frequency of increased carotid intimal-medial thickness (IMT) 110-
112.In an audit of 354 young adult patients with T2DM aged 15 to 30 years  ,marked increase of 
macrovascular disease in T2DMY compared to T1DM, including ischaemic heart disease and stroke 
was reported in an Australian hospital diabetes database112. While it is difficult to draw definitive 
conclusions from these observational studies, they suggest  that T2DMY is associated with a much 
more frequent occurrence of adverse macrovascular and microvascular outcomes and a more 
rapidly progressing severity of complications than TIDM or later-onset T2DM. 
 
Other complications  
 Complications such as impaired hearing and reduced fertility  are frequent in T2DMY and these can 
substantially reduce quality of life 113-115 . Risk of  premature  decline in cognitive function has been 
detected in T2DM presenting in middle and later life, and preliminary evidence suggests this could 
be even earlier in T2DMY and  have an important impact on healthcare and social welfare116,117  
 
TREATMENT 
 
There is little evidence to inform optimal strategies for the management of T2DMY and its rapidly 
developed complications: decisions are currently extrapolated from the evidence-based protocols 
that guide treatment of T2DM  presenting in older adults. The American Academy of Paediatrics2 and 
the ADA guidelines127 agree that the ideal goal of treatment in youth with T2DM is normalisation of 
glycaemic control to  reduce the risk of acute and chronic complications. Lifestyle modifications are 
prioritised , while  approved pharmaceutical agents can be considered in addition when lifestyle 
alone is inadequate.  The AACE guidelines128support a general approach that balances age, life 
expectancy and comorbidities, but there is no specific guidance according to age groups.  
 
 
 
 
Lifestyle changes 
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Although lifestyle modification is the most commonly used intervention in adolescents with T2DM,  
<20% achieve or maintain adequate glycaemic control with lifestyle therapy alone129,133. 
Interventions involving diet alone to treat T2DMY have been limited. A retrospective study of 20 
obese children and adolescents (mean age 14.5years) with T2DM reported improvements in weight 
(BMI fell  from 43.5 to 39.3 kg/m2 ), insulin sensitivity and HbA1c after introduction of a very 
low(<800Kcal/day) calorie diet  over a 2 month period. These improvements were, however, not 
maintained following cessation of the diet131. 
 
Aerobic activity, alone or in combination with diet, can reduce systolic blood pressure, lower total 
cholesterol, raise HDL-cholesterol and improve endothelial function in overweight T2DMY 53. 
However, any potential benefits to the CV risk profile are lost  within 3–6 months following cessation 
of exercise training, and do not confer protection against later CV events 53,133. Moreover, reviews of 
the limited number of studies to date have not identified significant or lasting benefits on glucose 
homeostasis of obese T2DMY patients undertaking additional aerobic exercise unless accompanied 
by dietary intervention 53,132,133.  
Pharmacological approaches 
 
There remains  great uncertainty in those younger than 18 years where concerns or lack of 
information about safety preclude or deter the use of many novel therapies. This is  compounded by  
difficulties  recruiting younger people into clinical trials. Both metformin and glibenclamide can be 
used effectively, at least in the short-term, in children and adolescents with T2DM.  Reduction in 
fasting plasma glucose (~1.2mmol/l) and HbA1c >1% has been reported with metformin monotherapy 
in children with T2DM aged 10 to 16 years135.   Significant lowering of  HbA1c was also shown in a 
study comparing metformin and glibenclamide as monotherapy and in combination:  interestingly, 
the combination was no more effective than either of these agents used alone136. 
Sustainability of glycaemic control with metformin +/- rosiglitazone was examined in the TODAY 
study - a randomised controlled trial of up to 6 years in a multiethnic cohort of 699 adolescents with 
T2DM diagnosed  age 10-17 years 137-138. Despite good treatment compliance, metformin as 
monotherapy or in combination with either rosiglitazone or lifestyle failed to sustain effective 
glycaemic control. At 1 year, treatment failure with metformin monotherapy was seen in 51.7%, 
compared to 46.6% in metformin plus lifestyle and 38.6% in the metformin plus rosiglitazone groups.  
High HbA1c and low insulin secretory capacity at baseline were independent predictors of risk for 
treatment failure (defined as HbA1c >8% for 6 months) 137. The study also highlighted ethnic 
differences in response to treatment with high failure rates amongst non-Hispanic blacks 137 (Table 
2).  
Rapid decline in beta-cell function may largely explain the faster loss of glycaemic control and the 
earlier requirement for insulin therapy in T2DMY than in T2DM (ref). Although some adolescents 
with T2DM can maintain glycaemic control for the first 2–3 years after diagnosis using lifestyle and 
metformin interventions90, insulin is often preferred as the initial therapy and about one third of 
those receiving basal insulin are able to subsequently stop insulin as glycaemic control improves 90,94.  
About half of these patients require re-initiation of insulin within a few months because of poor 
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control and some will require substantial insulin intensification94.  Based on the limited evidence to 
date, the types of insulins selected and the monitoring methods seem to make little difference to 
the glycaemic control achieved or the complication status139. Current evidence has not established a 
reduction in adverse CV events with rigorous control of CV risk factors in adolescents with T2DM. 
Several studies have reported that typically less than a third of these patients achieve their 
glycaemic or lipid targets and are less likely to be prescribed lipid lowering treatments, renin-
angiotensin-system inhibitors or anti-platelet agents than T2DM patients presenting in  later life 140-
143.  
 
Although many clinical trials in T2DM include individuals from age 18 onwards there are usually few 
young adults recruited and little data specific to the effectiveness of treatments in the age range 18-
40. Treatment approaches in this age group are therefore based on evidence from older T2DM 134. 
Several oral and injectable glucose lowering therapies are  approved for  T2DM and offer a wide 
choice in selecting appropriate therapeutic combinations. Many of these agents such as the DPP4 
inhibitors, GLP-1 agonists and SGLT2 inhibitors have beneficial effects on weight, insulin resistance 
and beta cell preservation. Whether they have a more favourable effect on the disease course in 
youth needs further investigation.  
 
Bariatric Surgery 
This has emerged as a viable treatment option in individuals with T2DM 144 and there is now 
evidence that it is safe and effective in obese adolescents145-146. Data in youth with type 2 diabetes 
are limited but nevertheless encouraging with significant improvements in weight and glycaemic 
indicators as seen in older adults (ref).  
 
 15 
 
STUDY 
STUDY 
TYPE 
NUMBER 
of Subjects 
 
ETHNICITY AGE 
RANGE 
(YEARS) 
DIABETES 
DURATION 
(YEARS) 
INTERVENTION  
AND FOLLOW UP 
FOLLOW UP 
(MONTHS) 
GLYCAEMIC OUTCOMES 
Wittmeier et 
al (2013)129 
 
 
 
Retrospe
ctive 
80  
 
 
 
 
89% First Nations 
5% Caucasian 
6% Other 
 
< 18 
 
< 1  
Lifestyle monotherapy  
 
12  
 
54% achieved HbA1c < 7%  
 
TODAY Study 
Group 
(2012)138 
 
RCT 699 
 
52.8% Non-Hispanic 
39.7% Hispanic 
7.5% Other 
10-17 
 
< 1 Group 1: Metformin alone 
Group 2: Metformin+Lifestyle 
Group 3: 
Metformin+Rosiglitazone  
45  
Metformin plus Rosiglitazone significantly 
superior to Metformin alone. 
Yeung et al 
(2014)141 
 
Cross 
sectional 
7481  
 
South/South east 
Asia 
 
< 40 
(mean age 
33) 
 
10 Insulin treatment alone or in 
combination with OHA 
 
n/a 
Only 27% of subjects achieved a HbA1c <7% 
Jones et al 
(2002)135 
 
 
 
 
 
RCT 82  
 
37% White 
30% Black 
22% Hispanic 
5% Asian 
6% Other 
8-16 n/a Group 1: Metformin 
Group 2: Placebo 
 
4 The mean HbA1c signiﬁcantly lower in the 
metformin group compared with the placebo 
(7.5% vs. 8.6%, respectively) 
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TABLE 2: Key studies showing the effectiveness of interventions to treat T2DMY.
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Societal impact of T2DMY 
 
The frequency and severity of complications with T2DMY may limit  capacity to work, and c  the  
economic and sociological sequelae are likely to be greater than for later-onset T2DM 147. Protracted 
depression requiring substantial on-going psychological support is common with T2DMY148, and 
reduced quality of life through visual impairment, frequency of healthcare appointments and 
lifestyle constraints are prominently cited by younger patients18., Pregnancy is not an uncommon 
occurrence in this age group and the presence of T2DMY can adversely affect maternal and foetal 
outcomes ( Add reference). Chronically disabling and life-threatening co-morbidities such as early 
onset end-stage renal disease, neuropathic pain and cardiovascular conditions present enormous  
challenges for patient wellbeing and large  potential costs for healthcare provision. The continued 
escalation of obesity and T2DM in young adults  also  impinges on the lives of other family members, 
friends, work colleagues, communities and the prosperity of localities where prevalence is 
particularly high 147,149.  Early onset obesity and T2DM have also been identified as particular threats 
to the capacity of healthcare services across Europe and North America, including predictions that 
current funding systems will not be able to accommodate the growing demands for expensive long-
term care incurred by the disease complications 3,147,150,151.Effective strategies aimed at preventing 
T2DMY are therefore needed to tackle this problem and the paucity of evidence in this area needs to 
be addressed urgently (Panel 1).   
 
 
Summary and Future research direction 
While it is tempting to extrapolate the natural history of T2DMY as just an earlier and more rapid 
form of later-onset T2DM, there are distinctive differences. The T2DMY phenotype has a stronger 
family history, greater obesity, early loss of both first and second phases of insulin secretion 
alongside often severe insulin resistance, early onset and rapid progression of micro- and 
macrovascular complications, and poor sustainability of responsiveness to oral glucose lowering 
therapies, frequently necessitating early introduction of insulin.     
Despite the many recognised genetic and environmental components of T2DMY, further elucidation 
of individual risk factors and their interactions is required to dissect the pathogenic process more 
closely and to better inform strategies for prevention and treatment (Panel 2). The paucity of 
evidence on long-term treatments and outcomes for T2DMY necessitates ongoing conventional 
clinical investigations to test and refine the use of current interventions.   Exploration of more 
effective ways to implement preventative lifestyle measures in the family setting and to improve 
health education in the school curriculum will be particularly valuable to enable younger individuals 
to appreciate the risks and make healthier lifestyle choices. The growing prevalence of T2DMY poses 
an extra devastating twist to the diabetes pandemic that requires strong public health messaging 
and investment from all stakeholders to mitigate a pending healthcare disaster.    
 
Panel 2: Knowledge gaps and areas for further research 
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